Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Studnicka

Showing results (1-10 of 108) with videos related to

Pageof 11
Sort By:
Wiener Medizinische Wochenschrift (1946)|May 12, 2005
[Epidemiology and prevention of COPD]Michael Studnicka
Wiener Klinische Wochenschrift|October 19, 2007
[COPD today and in the year 2020]Bernd Lamprecht, Michael Studnicka
The European Respiratory Journal|November 14, 2024
Going astray with a smoking <i>Traviata</i>?Joan B Soriano, Michael Studnicka
Lung|October 7, 2008
Electromagnetic navigation bronchoscopy in combination with PET-CT and rapid on-site cytopathologic examination for diagnosis of peripheral lung lesionsBernd Lamprecht, Peter Porsch, Christian Pirich, et al.
Lung Cancer (Amsterdam, Netherlands)|November 1, 2015
First line crizotinib in anaplastic lymphoma kinase (ALK) rearranged squamous cell lung cancerRomana E Mikes, Franziska Jordan, Georg Hutarew, et al.
Wiener Klinische Wochenschrift|October 19, 2007
[The prevalence of COPD in Austria--the expected change over the next decade]Natalie Firlei, Bernd Lamprecht, Lea Schirnhofer, et al.
Rheumatology International|June 3, 2026
Positive physician perceptions of structured lung ultrasound (LUS) training in interstitial lung disease (ILD): a post-workshop survey studyMirja M Wirtz, Stefanie Derenthal, Andrea Studnicka-Benke, et al.
Chest|February 9, 2020
COPD: Should Diagnosis Match Physiology?Michael Studnicka, Andreas Horner, Lea Sator, et al.
Thoracic Cancer|January 15, 2016
ROS1 mutation and treatment with crizotinib in a 30-year old Caucasian woman with stage IV non-small cell lung cancer/adenocarcinoma and complete remissionMarkus Blaukovitsch, Johann Hofer, Georg Hutarew, et al.
Current Medical Research and Opinion|March 1, 2013
Pegfilgrastim prophylaxis in patients at different levels of risk for chemotherapy-associated febrile neutropenia: an observational studyMichael Fiegl, Günther G Steger, Michael Studnicka, et al.
Pageof 11

Showing results (1-10 of 108) with videos related to

Sort By:
Pageof 11
Wiener Medizinische Wochenschrift (1946)|May 12, 2005
[Epidemiology and prevention of COPD]Michael Studnicka
Wiener Klinische Wochenschrift|October 19, 2007
[COPD today and in the year 2020]Bernd Lamprecht, Michael Studnicka
The European Respiratory Journal|November 14, 2024
Going astray with a smoking <i>Traviata</i>?Joan B Soriano, Michael Studnicka
Lung|October 7, 2008
Electromagnetic navigation bronchoscopy in combination with PET-CT and rapid on-site cytopathologic examination for diagnosis of peripheral lung lesionsBernd Lamprecht, Peter Porsch, Christian Pirich, et al.
Lung Cancer (Amsterdam, Netherlands)|November 1, 2015
First line crizotinib in anaplastic lymphoma kinase (ALK) rearranged squamous cell lung cancerRomana E Mikes, Franziska Jordan, Georg Hutarew, et al.
Wiener Klinische Wochenschrift|October 19, 2007
[The prevalence of COPD in Austria--the expected change over the next decade]Natalie Firlei, Bernd Lamprecht, Lea Schirnhofer, et al.
Rheumatology International|June 3, 2026
Positive physician perceptions of structured lung ultrasound (LUS) training in interstitial lung disease (ILD): a post-workshop survey studyMirja M Wirtz, Stefanie Derenthal, Andrea Studnicka-Benke, et al.
Chest|February 9, 2020
COPD: Should Diagnosis Match Physiology?Michael Studnicka, Andreas Horner, Lea Sator, et al.
Thoracic Cancer|January 15, 2016
ROS1 mutation and treatment with crizotinib in a 30-year old Caucasian woman with stage IV non-small cell lung cancer/adenocarcinoma and complete remissionMarkus Blaukovitsch, Johann Hofer, Georg Hutarew, et al.
Current Medical Research and Opinion|March 1, 2013
Pegfilgrastim prophylaxis in patients at different levels of risk for chemotherapy-associated febrile neutropenia: an observational studyMichael Fiegl, Günther G Steger, Michael Studnicka, et al.
Pageof 11